{
    "clinical_study": {
        "@rank": "142881", 
        "arm_group": {
            "arm_group_label": "NPB-01", 
            "arm_group_type": "Experimental", 
            "description": "Intravenous immunoglobulin"
        }, 
        "brief_summary": {
            "textblock": "Patients diagnosed with anti-aquaporin 4 antibody positive Neuromyelitis Optica spectrum\n      disorder were confirmed based on diagnostic criteria. Patients who meet all inclusion\n      criteria and do not conflict with the exclusion criteria will receive steroid plus therapy\n      \uff081g/day for five consecutive days\uff09. Subsequently, patients who not provided adequate effect\n      of therapy to steroids plus therapy will receive NPB-01 (intravenous immunoglobulin)\n      400mg/kg/day for five consecutive days. Patients evaluated Quantification of nerve and\n      spinal cord impairment \uff08QOSI\uff09 and the Expanded Disability Status Scale \uff08EDSS\uff09/ Functional\n      Systems \uff08FS\uff09 and anti-aquaporin 4 antibody et al.\n\n      As a safety endpoint, the safety of NPB-01 will be investigated the occurrence of adverse\n      events by one year after the start of the study treatment."
        }, 
        "brief_title": "Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Neuromyelitis Optica Spectrum Disorder", 
        "condition_browse": {
            "mesh_term": "Neuromyelitis Optica"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients who become positive for anti-aquaporin 4 antibody or have becomed.\n\n          2. Patients who have developed myelitis.\n\n          3. Patients who run beyond greater than 30 days at least from last time in relapse.\n\n          4. Patients who new neurological symptom or worsening neurological symptom or flared\n             neurological symptom have sustained 24 hours at least not associated fever or\n             infection.\n\n          5. Patients who have an acute exacerbation at informed consent.\n\n          6. Patients who need steroid plus therapy\uff081g/day for five consecutive days\uff09.\n\n          7. Patients who can start steroid plus therapy within 3 days after informed consent.\n\n          8. Patients who be inadequate to effect to steroid plus therapy.\n\n          9. Patients with greater than or equal to twenty years old at informed consent.\n\n        Exclusion Criteria:\n\n          1. Patients who have developed optic neuritis.\n\n          2. Patients treated with intravenous immunoglobulin within 14 days before informed\n             consent.\n\n          3. Patients with malignancy at informed consent.\n\n          4. Patients with history of shock or hypersensitivity for NPB-01.\n\n          5. Patients with IgA deficiency.\n\n          6. Patients with impaired liver function.\n\n          7. Patients with impaired renal function.\n\n          8. Patients with cerebro- or cardiovascular disorders.\n\n          9. Patients with high risk of thromboembolism.\n\n         10. Patients with hemolytic/hemorrhagic anemia.\n\n         11. Patients with decreased cardiac function.\n\n         12. Patients with decreased platelet."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "7", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01845584", 
            "org_study_id": "NPB-01-08/E-01"
        }, 
        "intervention": {
            "arm_group_label": "NPB-01", 
            "intervention_name": "NPB-01", 
            "intervention_type": "Drug", 
            "other_name": "Intravenous immunoglobulin"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Immunoglobulins", 
                "Immunoglobulins, Intravenous", 
                "Rho(D) Immune Globulin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "IVIG in Neuromyelitis Optica spectrum disorder", 
            "Patients with Neuromyelitis Optica spectrum disorder"
        ], 
        "lastchanged_date": "July 10, 2013", 
        "location": {
            "contact": {
                "email": "kaihatsu@nihon-pharm.co.jp", 
                "last_name": "Yasumasa Ogawa"
            }, 
            "facility": {
                "address": {
                    "city": "Osaka,", 
                    "country": "Japan"
                }, 
                "name": "Japan"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Change from Baseline Quantification of nerve and spinal cord impairment \uff08QOSI\uff09 at 29 days", 
                "safety_issue": "No", 
                "time_frame": "29 days"
            }, 
            {
                "measure": "Change from Baseline Expanded Disability Status Scale \uff08EDSS\uff09/ Functional Systems \uff08FS\uff09 at 29 days", 
                "safety_issue": "No", 
                "time_frame": "29 days"
            }, 
            {
                "measure": "Change from Baseline anti-aquaporin 4 antibody at 29 days", 
                "safety_issue": "No", 
                "time_frame": "29 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01845584"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Nihon Pharmaceutical Co., Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nihon Pharmaceutical Co., Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}